Safety Study of XL147 in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors



Status:Archived
Conditions:Lung Cancer, Ovarian Cancer, Cervical Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:September 2008
End Date:April 2010

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors


The purpose of this study is to evaluate the safety and tolerability of XL147 in combination
with paclitaxel and carboplatin in adults with solid tumors. XL147 is a new chemical entity
that inhibits PI3 Kinase. Inactivation of PI3K has been shown to inhibit growth and induce
apoptosis (programmed cell death) in tumor cells. In clinical practice, the combination of
paclitaxel and carboplatin is an accepted treatment regimen for various solid tumors,
including ovarian cancer, endometrial cancer and non-small cell lung cancer (NSCLC).



We found this trial at
2
sites
University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
University of Wisconsin-Madison, Department of Dermatology
Madison, Wisconsin 53715
?
mi
from
Madison, WI
Click here to add this to my saved trials